Form 4: Hims & Hers CFO Granted 300,978 Restricted Stock Units

Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe was granted 300,978 Restricted Stock Units, vesting over four years.

Summary

• Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), acquired 300,978 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was March 11, 2026.
• Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs are subject to a service-based vesting requirement over a 4-year period.
• Vesting will occur in substantially equal quarterly installments on March 15, June 15, September 15, and December 15.
• The first vesting date is scheduled for June 15, 2026.
• Following this transaction, Oluyemi Okupe beneficially owns 300,978 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating continued executive commitment and alignment with long-term company performance through a standard compensation mechanism.

Positives

• The grant of Restricted Stock Units to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing sustained company performance.
• This compensation structure encourages executive retention through its multi-year vesting schedule.

Negatives

• The RSUs do not provide immediate cash value to the CFO and are subject to forfeiture if vesting conditions (service-based) are not met.
• The ultimate value of the RSUs is dependent on the future market price of Hims & Hers Health, Inc. Class A Common Stock.

Risks

• The value of the RSUs is subject to the market price fluctuations of Hims & Hers Health, Inc. Class A Common Stock.
• Vesting of the RSUs is contingent on continued employment, posing a risk of forfeiture if the service-based requirements are not met.

Future Outlook

The grant of RSUs with a four-year vesting schedule indicates a long-term commitment from the Chief Financial Officer to the company's future performance and strategic objectives.

Industry Context

StockSavvy.ai notes that RSU grants are a common and widely accepted form of executive compensation in the technology and healthcare industries, particularly for growth-oriented companies like Hims & Hers. This practice is designed to align the interests of key executives with long-term shareholder value creation and to incentivize retention.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across the technology and healthcare sectors, comparable to compensation structures at companies like Teladoc Health (TDOC) or GoodRx (GDRX).
• A four-year vesting schedule is typical for RSU grants, providing a balance between immediate incentive and long-term commitment, similar to programs seen at many publicly traded peers.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the CFO's financial interests with long-term shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: This compensation structure for a key executive may serve as a benchmark or signal for broader employee incentive programs, though it is specific to executive compensation.

Next Steps

• The Restricted Stock Units will begin vesting on June 15, 2026, and continue quarterly over the subsequent four years, contingent on the CFO's continued service.

Key Dates

Keywords

Hims & Hers Health, HIMS, Oluyemi Okupe, CFO, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Stock Grant, Corporate Governance